Retatrutide is often called "GLP-3" in online communities because it targets three receptors: GLP-1, GIP, and Glucagon
However, they can still impact the endocrine system, insulin sensitivity, and IGF-1 axis with prolonged or high-dose use
GLP-1RAs exert glycemic control through multiple mechanisms, including the stimulation of insulin secretion under hyperglycemic conditions, suppression of glucagon secretion during hyperglycemia, deceleration of gastric emptying to mitigate postprandial glucose spikes, reduction of caloric intake, and promotion of weight loss.71,8183 Short-acting GLP-1RAs, such as exenatide and lixisenatide, primarily reduce nocturnal and fasting glucose levels, while maintaining their effect on gastric emptying over prolonged treatment periods
2,3 However, safety concerns, particularly around cancer risk, have persisted since early rodent thyroid studies
10.3390/nano11020460 24 BhartiA